Developer docs
API playgroundTry for free, no card

Search company profiles

Globalpharma

Full company profile

uuid0009m67

Namestring
Globalpharma
Legal namestring
GLOBALPHARMA CO. (L.L.C.)
Websiteurl
globalpharma.ae
Company typeenum
Private
Founded yearint
1998
Descriptiontext

Globalpharma Co. (L.L.C.) is a Dubai-based generic pharmaceutical manufacturer founded in 1998 and headquartered at Dubai Investment Park. It operates a 27,000 m2 cGMP-certified manufacturing complex comprising a dedicated Beta-Lactam Penicillin plant (producing Amoxicillin and AmoxiClav under the Gloclav and Glomox brands) and a General Medicine plant with annual capacity of 300 million tablets, 150 million capsules, and over 3 million litres of dry suspension and liquid. The portfolio has grown from 2 products at inception to more than 90 SKUs spanning anti-infectives, cardiovascular, anti-diabetics, anti-ulcerants, NSAIDs and analgesics, respiratory, antihistamines, vitamins and supplements, and herbal medicines (MG21, CG21). Recent additions include EU-certified Oral Disposible Film (ODF) technology licensed from ZIM Laboratories (India) in April 2025 and 25 new product launches planned for 2025.

The company sells through a B2B pharmaceutical distribution model targeting major hospitals, chain pharmacy groups, and government health authorities across 14+ countries in the GCC, broader Middle East, Africa, and CIS. Key channel partners include Wasfaty in Saudi Arabia — a major driver of the 139.5% year-over-year Saudi sales growth to $12.6M by May 2024 — and Alphamed for UAE herbal distribution. Trailing twelve months sales (June 2023 to May 2024) reached $70.3M, up 44.7% year-over-year, with first-five-months 2024 sales of $33.2M representing 78.6% growth. Pricing is quote-based, set through tenders and distributor agreements; the company is privately held as a wholly-owned subsidiary of Dubai Investments PJSC, a publicly listed diversified group on the Dubai Financial Market.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersDubai, United Arab Emirates
HQ citystring
Dubai
HQ countrystring
United Arab Emirates
HQ regionstring
Middle East
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
generic pharmaceuticals, pharmaceutical manufacturing, beta-lactam antibiotics, herbal medicines, oral dispersible films
Industry7 codes
PRIMARYHLAIABAH
Generic Finished Dosage Form (FDF) Manufacturing
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAJAB
Specialty Pharmaceutical Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYHLAIAJAF
Government & Public-Sector Pharmaceutical Supply (Tender/Prime Vendor)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYCRADAGAB
Vitamins & Minerals (Single Nutrients)
SECONDARYCRADAMAD
Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges)
Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Health & Hygiene OTC Consumer Goods (First Aid, Oral Care, Personal Health)
NAICS code4 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
  • Medicinal and Botanical Manufacturing325411
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
SIC code3 codes
  • Pharmaceutical Preparations2834
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
  • Medicinal Chemicals & Botanical Products2833
Product category
Generic Pharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Generic Pharmaceutical Product Sales
TypeOne Time License
Description

Manufacturing and commercializing generic pharmaceutical products across multiple therapeutic segments including antibiotics, cardiovascular, anti-ulcerants, analgesics, NSAIDs, food supplements, vitamins, anti-diabetics, respiratory products, and anti-histamine formulations. Revenue generated through product sales to distributors, hospitals, and pharmacies across GCC, Middle East, and African markets.

globalpharma.ae:443
2Herbal Medicines Distribution
TypeOne Time License
Description

Distribution of herbal medicines including MG21 through Alphamed distribution agreement across Middle East pharmacies.

globalpharma.ae
3Consumer Health Products (GP+ Brand)
TypeOne Time License
Description

Manufacturing and distribution of consumer health products including hand sanitizers and face masks under the GP+ brand during and post-pandemic.

globalpharma.ae
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure
Pricing details1 tier
1Pharmaceutical products sold in various pack sizes and formulations
ModelOtherBilling cadencePay-as-you-go
Notes

Products available in various dosage forms including tablets, capsules, syrups, and suspensions. Pricing determined through tender processes and distributor agreements.

globalpharma.ae
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1GP+
Description

Hand sanitizer and facemask brand launched in 2020 during COVID-19 pandemic. GP+ hand sanitizers are approved by Dubai Municipality and manufactured per WHO guidelines with 75% Isopropyl alcohol, available in 100ml and 250ml spray bottles.

globalpharma.ae
+2 more records
Core offering1 text field

Globalpharma manufactures and commercializes generic pharmaceutical products across multiple therapeutic segments including anti-infectives, cardio-metabolic, NSAIDs/pain killers, anti-ulcerants, anti-diabetics, respiratory, anti-histamine, vitamins, and herbal medicines. The company operates cGMP-certified manufacturing facilities in Dubai Investment Park covering 27,000 m2 with annual capacity of 300 million tablets, 150 million capsules, and over 7 million litres of dry syrup and liquid, producing more than 90 products sold across 14+ countries in the GCC, Middle East, and African markets.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Globalpharma is a pharmaceutical manufacturer specializing in generic medicines, established in 1998 and headquartered in Dubai Investments Park. The company operates two state-of-the-art manufacturing plants: a Beta-Lactam Penicillin Manufacturing plant providing Amoxicillin & AmoxiClav brands (Gloclav, Glomox) and a General Medicine Manufacturing Plant with Liquid & Oral Solid Dose capabilities. Globalpharma manufactures and distributes more than 90 products across lifestyle disease segments including Cardiovasculars (Sartan, Irvel, Atorlip, Rosuvastatin, RUSET, Glovadip), Anti-ulcerants (Emilok), Anti-Diabetics (Emivanz, Emipride), Anti-Arthritis/Analgesics including NSAIDs (Emifenac DT, Emidol, Emifen, Algoxib), Respiratory, Anti-histamine formulations (Glozal, Emilora, Glotrizine, Gloditen, EzeAir), Anti-infectives (Gloclav, Glomox, Emicipro, Emimycin, Levotab), and Multivitamin supplements (Glovit family). The company also produces herbal medicines including MG21 and CG21, and consumer health products like GP+ sanitizers and face masks. All manufacturing facilities are cGMP certified and approved by health authorities across GCC, UAE, Saudi FDA, Levant, Africa, and CIS regions.

Product and service16 records
1Gloclav (Amoxicillin + Clavulanate Potassium)
CategoryAnti-Infective
Description

Beta-lactam penicillin antibiotic available in tablet and oral suspension forms for treating bacterial infections. Flagship brand providing Amoxicillin & AmoxiClav in the larger MENA region.

2Glomox (Amoxicillin)
CategoryAnti-Infective
Description

Amoxicillin antibiotic available in capsules, tablets and oral suspension forms for treating various bacterial infections.

3Emifenac DT (Diclofenac Dispersible)
CategoryNSAID / Pain Killer
Description

Diclofenac dispersible tablet for pain and inflammation management. One of the company's well-respected brands across Middle East & North African markets.

4Emidol (Paracetamol)
CategoryNSAID / Pain Killer
Description

Paracetamol analgesic available in tablets, syrup and suspension forms for pain and fever relief.

5Glovit Softgels (Multivitamin)
CategoryVitamin / Supplement
Description

Multivitamin supplement brand trusted by healthcare professionals for quality and proven efficacy, part of the multivitamin range.

6MG21 Herbal Medicine
CategoryHerbal Medicine
Description

Herbal anti-inflammatory medicine consisting of pure extract of Myrrh and Costus, used for treatment and prevention of respiratory infections, indigestion, skin infections, headaches and diabetic conditions. First herbal product manufactured at the company's MOHAP-approved herbal manufacturing line.

7CG21 Herbal Medicine
CategoryHerbal Medicine
Description

Herbal anti-inflammatory medicine inspired by UAE heritage, incorporating a distinctive formulation blending Cloves and Costus, succeeding MG21.

8RUSET (Rosuvastatin + Ezetimibe)
CategoryCardio-Metabolic
Description

Combination lipid-lowering medication with Rosuvastatin and Ezetimibe, available in four distinct SKUs for dyslipidaemia management. Latest addition to Cardio-Metabolic franchise.

9Glovadip (Valsartan + Amlodipine)
CategoryCardio-Metabolic
Description

Combination antihypertensive medication combining Valsartan and Amlodipine for blood pressure management.

10Uriout (Febuxostat)
CategoryCardio-Metabolic
Description

Febuxostat xanthine oxidase inhibitor for chronic gout management.

11GP+ Hand Sanitizer
CategoryConsumer Health Product
Description

UAE-made hand rub sanitizer containing 75% Isopropyl alcohol, approved by Dubai Municipality and manufactured according to WHO guidelines. Available in 100ml and 250ml spray bottles.

12GP+ Surgical Face Masks
CategoryConsumer Health Product
Description

UAE-made surgical disposable face masks with high-quality melt blown filter offering highest filtration rate, produced under UV sterilization at GMP-compliant facilities.

13Sartan / Emisartan (Losartan) and Sartan H / Emisartan H (Losartan/HCT)
CategoryCardio-Metabolic
Description

Losartan angiotensin receptor blocker for hypertension management, available in 50mg and 100mg tablets, also combined with hydrochlorothiazide (HCT) for enhanced blood pressure control.

14Emivanz (Metformin + Glibenclamide) and Emipride (Glimepiride)
CategoryCardio-Metabolic
Description

Combination antidiabetic medications for Type 2 diabetes management, including Metformin HCl + Glibenclamide combination and Glimepiride sulfonylurea in 1mg, 2mg, and 3mg tablets.

15Allergy product line (Glozal, Emilora/Glora, Glotrizine, Gloditen, EzeAir)
CategoryAllergy
Description

Anti-histamine product line including Levocetirizine, Loratadine, Cetirizine, Ketotifen, and Montelukast for allergy and asthma treatment in tablets, chewable tablets, and syrup forms.

16Emilok (Omeprazole) and Zaeer/Glofel (Tadalafil)
CategoryOther Therapeutics
Description

Other therapeutic products including Omeprazole proton pump inhibitor in 20mg and 40mg capsules for acid-related disorders, and Tadalafil in 5mg and 20mg tablets for erectile dysfunction.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-04-07
Description

Partnership to bring EU-certified Oral Dispersible Film (ODF) technology to UAE and the Middle East. The ODF technology offers thin, fast-dissolving strips that melt in the mouth without water, ideal for children, elderly patients, and those with swallowing difficulties. The agreement was signed at AIM Congress 2025 and witnessed by H.E. Dr. Thani bin Ahmed Al Zeyoudi, Minister of State for Foreign Trade. Globalpharma is establishing a dedicated production line with a growing portfolio of ten ODF products.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-12-21
Description

Strategic collaboration for the development, manufacturing, marketing, promotion and distribution of MG21 herbal anti-inflammatory medicine across the Middle East. Globalpharma inaugurated the first MOHAP approved herbal manufacturing line at its Dubai Investments Park facility. Al Fujairah Healing Company selected Globalpharma to produce and distribute MG21, which is estimated to yield an annual production capacity of around half million capsules.

Strategic tierMajorTypeChannel Partner/ Reseller/ Distributor
Description

Distribution agreement signed with Alphamed, one of the leading local suppliers in the UAE, to ensure availability of MG21 herbal medicine in the majority of pharmacies before the end of the launch year.

4Wasfaty
Strategic tierMajorTypeChannel Partner/ Reseller/ Distributor
Description

Strategic partnership in Saudi Arabia for market access and distribution of Globalpharma products, contributing to the company's remarkable 139.5% year-over-year sales growth in the Saudi market.

globalpharma.ae
Strategic tierMinorTypeOthers
Description

Humanitarian partnership for earthquake relief efforts. Globalpharma supplied more than 144,000 packs of generic medicines including anti-inflammatories, analgesics, antiseptics, sanitisers, food supplements and anti-infectives to victims in Turkey and Syria in collaboration with Emirates Red Crescent.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Julphar (Gulf Pharmaceutical Industries)
TypeDirect peer
Description

UAE-headquartered generic pharmaceutical manufacturer with broad MENA distribution, multi-therapeutic portfolio, and similar B2B/tender GTM. Closest direct competitor to Globalpharma in the UAE generics landscape.

TypeDirect peer
Description

Abu Dhabi-based generic pharmaceutical manufacturer with manufacturing facilities in the UAE, India, and other emerging markets. Competes head-to-head with Globalpharma across GCC tenders and lifestyle disease therapeutics.

TypeDirect peer
Description

Saudi-listed generic pharmaceutical manufacturer with manufacturing in KSA and a strong Wasfaty/government tender presence — a direct peer competing for the same Saudi contracts driving Globalpharma's recent growth.

TypeDirect peer
Description

Saudi Arabia-based pharmaceutical company with branded generics, biosimilars, and specialty portfolio across MENA. Competes with Globalpharma in cardiovascular, anti-infectives, and CNS categories throughout the GCC.

TypeDirect peer
Description

Jordan-headquartered global generic pharmaceutical manufacturer with strong MENA footprint and growing injectables/specialty franchise. The largest MENA-rooted generics peer and a benchmark for Globalpharma's regional ambitions.

TypeRegional player
Description

Egypt-based generic pharmaceutical manufacturer with large domestic share and exports to GCC/Africa. Adjacent regional peer competing for the same African and Arab League tender markets Globalpharma targets.

TypeEmerging player
Description

Indian-based global generic manufacturer with extensive API and finished dosage manufacturing, increasingly competing in MENA tenders on price. A cost-competitive threat to Globalpharma's commodity generic portfolio.

TypeEmerging player
Description

Indian-headquartered global generic and specialty pharmaceutical manufacturer with established presence in Africa and growing Middle East footprint. Competes with Globalpharma across respiratory, cardiovascular, and anti-infective categories.

9Sun Pharmaceutical Industries
TypeEmerging player
Description

One of the largest Indian generic pharmaceutical companies with global manufacturing and distribution. Competes for MENA tenders and emerging-market share with Globalpharma across chronic disease therapies.

TypeBroad incumbent
Description

Global pharmaceutical major with significant MENA manufacturing and commercial operations across branded specialty and generics. Serves as a broader benchmark for cardiovascular and metabolic portfolio breadth that Globalpharma is expanding into.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance10 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Globalpharma

Generic Pharmaceuticalsglobalpharma.ae

What Globalpharma does

Globalpharma Co. (L.L.C.) is a Dubai-based generic pharmaceutical manufacturer founded in 1998 and headquartered at Dubai Investment Park. It operates a 27,000 m2 cGMP-certified manufacturing complex comprising a dedicated Beta-Lactam Penicillin plant (producing Amoxicillin and AmoxiClav under the Gloclav and Glomox brands) and a General Medicine plant with annual capacity of 300 million tablets, 150 million capsules, and over 3 million litres of dry suspension and liquid. The portfolio has grown from 2 products at inception to more than 90 SKUs spanning anti-infectives, cardiovascular, anti-diabetics, anti-ulcerants, NSAIDs and analgesics, respiratory, antihistamines, vitamins and supplements, and herbal medicines (MG21, CG21). Recent additions include EU-certified Oral Disposible Film (ODF) technology licensed from ZIM Laboratories (India) in April 2025 and 25 new product launches planned for 2025.

The company sells through a B2B pharmaceutical distribution model targeting major hospitals, chain pharmacy groups, and government health authorities across 14+ countries in the GCC, broader Middle East, Africa, and CIS. Key channel partners include Wasfaty in Saudi Arabia — a major driver of the 139.5% year-over-year Saudi sales growth to $12.6M by May 2024 — and Alphamed for UAE herbal distribution. Trailing twelve months sales (June 2023 to May 2024) reached $70.3M, up 44.7% year-over-year, with first-five-months 2024 sales of $33.2M representing 78.6% growth. Pricing is quote-based, set through tenders and distributor agreements; the company is privately held as a wholly-owned subsidiary of Dubai Investments PJSC, a publicly listed diversified group on the Dubai Financial Market.

Globalpharma firmographics

Firmographics
Name
Globalpharma
Legal name
GLOBALPHARMA CO. (L.L.C.)
Website
https://globalpharma.ae
Company type
Private
Founded year
1998
Operating status
Operating
Headcount range
251–500 employees
Ownership category
akta.pro rank

Globalpharma industry classification

Industry
Product category
Generic Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Medicinal and Botanical Manufacturing (325411), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
SIC
Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAIABAH
Generic Finished Dosage Form (FDF) Manufacturing
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAJAB
Specialty Pharmaceutical Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYHLAIAJAF
Government & Public-Sector Pharmaceutical Supply (Tender/Prime Vendor)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYCRADAGAB
Vitamins & Minerals (Single Nutrients)
SECONDARYCRADAMAD
Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges)
Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Health & Hygiene OTC Consumer Goods (First Aid, Oral Care, Personal Health)

Keywords

  • Generic pharmaceuticals
  • Pharmaceutical manufacturing
  • Beta-lactam antibiotics
  • Herbal medicines
  • Oral dispersible films

Where Globalpharma is headquartered

Location

Headquarters

HQ city
Dubai
HQ country
United Arab Emirates
HQ region
Middle East

Offices3 records

Markets served

Globalpharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Generic Pharmaceutical Product Sales: Manufacturing and commercializing generic pharmaceutical products across multiple therapeutic segments including antibiotics, cardiovascular, anti-ulcerants, analgesics, NSAIDs, food supplements, vitamins, anti-diabetics, respiratory products, and anti-histamine formulations. Revenue generated through product sales to distributors, hospitals, and pharmacies across GCC, Middle East, and African markets.
  2. Herbal Medicines Distribution: Distribution of herbal medicines including MG21 through Alphamed distribution agreement across Middle East pharmacies.
  3. Consumer Health Products (GP+ Brand): Manufacturing and distribution of consumer health products including hand sanitizers and face masks under the GP+ brand during and post-pandemic.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goPharmaceutical products sold in various pack sizes and formulations

Go-to-market motion1 record

Distribution channels5 records

Marketing channels6 records

Globalpharma product offering

Product offering

Core offering

Globalpharma manufactures and commercializes generic pharmaceutical products across multiple therapeutic segments including anti-infectives, cardio-metabolic, NSAIDs/pain killers, anti-ulcerants, anti-diabetics, respiratory, anti-histamine, vitamins, and herbal medicines. The company operates cGMP-certified manufacturing facilities in Dubai Investment Park covering 27,000 m2 with annual capacity of 300 million tablets, 150 million capsules, and over 7 million litres of dry syrup and liquid, producing more than 90 products sold across 14+ countries in the GCC, Middle East, and African markets.

Product overview

Globalpharma is a pharmaceutical manufacturer specializing in generic medicines, established in 1998 and headquartered in Dubai Investments Park. The company operates two state-of-the-art manufacturing plants: a Beta-Lactam Penicillin Manufacturing plant providing Amoxicillin & AmoxiClav brands (Gloclav, Glomox) and a General Medicine Manufacturing Plant with Liquid & Oral Solid Dose capabilities. Globalpharma manufactures and distributes more than 90 products across lifestyle disease segments including Cardiovasculars (Sartan, Irvel, Atorlip, Rosuvastatin, RUSET, Glovadip), Anti-ulcerants (Emilok), Anti-Diabetics (Emivanz, Emipride), Anti-Arthritis/Analgesics including NSAIDs (Emifenac DT, Emidol, Emifen, Algoxib), Respiratory, Anti-histamine formulations (Glozal, Emilora, Glotrizine, Gloditen, EzeAir), Anti-infectives (Gloclav, Glomox, Emicipro, Emimycin, Levotab), and Multivitamin supplements (Glovit family). The company also produces herbal medicines including MG21 and CG21, and consumer health products like GP+ sanitizers and face masks. All manufacturing facilities are cGMP certified and approved by health authorities across GCC, UAE, Saudi FDA, Levant, Africa, and CIS regions.

Differentiator

Problem solved

Functional benefit

Brands

  • GP+: Hand sanitizer and facemask brand launched in 2020 during COVID-19 pandemic. GP+ hand sanitizers are approved by Dubai Municipality and manufactured per WHO guidelines with 75% Isopropyl alcohol, available in 100ml and 250ml spray bottles.
  • MG21
  • CG21

Products and services

  • Gloclav (Amoxicillin + Clavulanate Potassium) Beta-lactam penicillin antibiotic available in tablet and oral suspension forms for treating bacterial infections. Flagship brand providing Amoxicillin & AmoxiClav in the larger MENA region.
  • Glomox (Amoxicillin) Amoxicillin antibiotic available in capsules, tablets and oral suspension forms for treating various bacterial infections.
  • Emifenac DT (Diclofenac Dispersible) Diclofenac dispersible tablet for pain and inflammation management. One of the company's well-respected brands across Middle East & North African markets.
  • Emidol (Paracetamol) Paracetamol analgesic available in tablets, syrup and suspension forms for pain and fever relief.
  • Glovit Softgels (Multivitamin) Multivitamin supplement brand trusted by healthcare professionals for quality and proven efficacy, part of the multivitamin range.
  • MG21 Herbal Medicine Herbal anti-inflammatory medicine consisting of pure extract of Myrrh and Costus, used for treatment and prevention of respiratory infections, indigestion, skin infections, headaches and diabetic conditions. First herbal product manufactured at the company's MOHAP-approved herbal manufacturing line.
  • CG21 Herbal Medicine Herbal anti-inflammatory medicine inspired by UAE heritage, incorporating a distinctive formulation blending Cloves and Costus, succeeding MG21.
  • RUSET (Rosuvastatin + Ezetimibe) Combination lipid-lowering medication with Rosuvastatin and Ezetimibe, available in four distinct SKUs for dyslipidaemia management. Latest addition to Cardio-Metabolic franchise.
  • Glovadip (Valsartan + Amlodipine) Combination antihypertensive medication combining Valsartan and Amlodipine for blood pressure management.
  • Uriout (Febuxostat) Febuxostat xanthine oxidase inhibitor for chronic gout management.
  • GP+ Hand Sanitizer UAE-made hand rub sanitizer containing 75% Isopropyl alcohol, approved by Dubai Municipality and manufactured according to WHO guidelines. Available in 100ml and 250ml spray bottles.
  • GP+ Surgical Face Masks UAE-made surgical disposable face masks with high-quality melt blown filter offering highest filtration rate, produced under UV sterilization at GMP-compliant facilities.
  • Sartan / Emisartan (Losartan) and Sartan H / Emisartan H (Losartan/HCT) Losartan angiotensin receptor blocker for hypertension management, available in 50mg and 100mg tablets, also combined with hydrochlorothiazide (HCT) for enhanced blood pressure control.
  • Emivanz (Metformin + Glibenclamide) and Emipride (Glimepiride) Combination antidiabetic medications for Type 2 diabetes management, including Metformin HCl + Glibenclamide combination and Glimepiride sulfonylurea in 1mg, 2mg, and 3mg tablets.
  • Allergy product line (Glozal, Emilora/Glora, Glotrizine, Gloditen, EzeAir) Anti-histamine product line including Levocetirizine, Loratadine, Cetirizine, Ketotifen, and Montelukast for allergy and asthma treatment in tablets, chewable tablets, and syrup forms.
  • Emilok (Omeprazole) and Zaeer/Glofel (Tadalafil) Other therapeutic products including Omeprazole proton pump inhibitor in 20mg and 40mg capsules for acid-related disorders, and Tadalafil in 5mg and 20mg tablets for erectile dysfunction.

Companies that use Globalpharma

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles4 records

Globalpharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Globalpharma partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core, major and minor.

  • ZIM Laboratories (India)coreTechnology or Integration · 7 April 2025Partnership to bring EU-certified Oral Dispersible Film (ODF) technology to UAE and the Middle East. The ODF technology offers thin, fast-dissolving strips that melt in the mouth without water, ideal for children, elderly patients, and those with swallowing difficulties. The agreement was signed at AIM Congress 2025 and witnessed by H.E. Dr. Thani bin Ahmed Al Zeyoudi, Minister of State for Foreign Trade. Globalpharma is establishing a dedicated production line with a growing portfolio of ten ODF products.
  • Al Fujairah Healing CompanycoreStrategic or Co-development Partner · 21 December 2021Strategic collaboration for the development, manufacturing, marketing, promotion and distribution of MG21 herbal anti-inflammatory medicine across the Middle East. Globalpharma inaugurated the first MOHAP approved herbal manufacturing line at its Dubai Investments Park facility. Al Fujairah Healing Company selected Globalpharma to produce and distribute MG21, which is estimated to yield an annual production capacity of around half million capsules.
  • AlphamedmajorChannel Partner/ Reseller/ DistributorDistribution agreement signed with Alphamed, one of the leading local suppliers in the UAE, to ensure availability of MG21 herbal medicine in the majority of pharmacies before the end of the launch year.
  • WasfatymajorChannel Partner/ Reseller/ DistributorStrategic partnership in Saudi Arabia for market access and distribution of Globalpharma products, contributing to the company's remarkable 139.5% year-over-year sales growth in the Saudi market.
  • Emirates Red CrescentminorOthersHumanitarian partnership for earthquake relief efforts. Globalpharma supplied more than 144,000 packs of generic medicines including anti-inflammatories, analgesics, antiseptics, sanitisers, food supplements and anti-infectives to victims in Turkey and Syria in collaboration with Emirates Red Crescent.

Scale indicators10 records

Recent moves8 records

Expansion highlights6 records

Globalpharma competitors and assessment

Company assessment

Direct peers

  • Julphar (Gulf Pharmaceutical Industries): UAE-headquartered generic pharmaceutical manufacturer with broad MENA distribution, multi-therapeutic portfolio, and similar B2B/tender GTM. Closest direct competitor to Globalpharma in the UAE generics landscape.
  • Neopharma: Abu Dhabi-based generic pharmaceutical manufacturer with manufacturing facilities in the UAE, India, and other emerging markets. Competes head-to-head with Globalpharma across GCC tenders and lifestyle disease therapeutics.
  • SPIMACO Addwaeih: Saudi-listed generic pharmaceutical manufacturer with manufacturing in KSA and a strong Wasfaty/government tender presence — a direct peer competing for the same Saudi contracts driving Globalpharma's recent growth.
  • Tabuk Pharmaceuticals: Saudi Arabia-based pharmaceutical company with branded generics, biosimilars, and specialty portfolio across MENA. Competes with Globalpharma in cardiovascular, anti-infectives, and CNS categories throughout the GCC.
  • Hikma Pharmaceuticals: Jordan-headquartered global generic pharmaceutical manufacturer with strong MENA footprint and growing injectables/specialty franchise. The largest MENA-rooted generics peer and a benchmark for Globalpharma's regional ambitions.

Regional players

Emerging players

  • Aurobindo Pharma: Indian-based global generic manufacturer with extensive API and finished dosage manufacturing, increasingly competing in MENA tenders on price. A cost-competitive threat to Globalpharma's commodity generic portfolio.
  • Cipla: Indian-headquartered global generic and specialty pharmaceutical manufacturer with established presence in Africa and growing Middle East footprint. Competes with Globalpharma across respiratory, cardiovascular, and anti-infective categories.
  • Sun Pharmaceutical Industries: One of the largest Indian generic pharmaceutical companies with global manufacturing and distribution. Competes for MENA tenders and emerging-market share with Globalpharma across chronic disease therapies.

Broad incumbents

  • Sanofi (MENA operations): Global pharmaceutical major with significant MENA manufacturing and commercial operations across branded specialty and generics. Serves as a broader benchmark for cardiovascular and metabolic portfolio breadth that Globalpharma is expanding into.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Globalpharma social profiles

Digital presence

Globalpharma compliance and trust

Trust signal

Compliance10 records

Globalpharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Globalpharma leadership team

Management profile

Number of profiles

Profiles4 records

Globalpharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Globalpharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Globalpharma

What does Globalpharma do?

Globalpharma manufactures and commercializes generic pharmaceutical products across multiple therapeutic segments including anti-infectives, cardio-metabolic, NSAIDs/pain killers, anti-ulcerants, anti-diabetics, respiratory, anti-histamine, vitamins, and herbal medicines. The company operates cGMP-certified manufacturing facilities in Dubai Investment Park covering 27,000 m2 with annual capacity of 300 million tablets, 150 million capsules, and over 7 million litres of dry syrup and liquid, producing more than 90 products sold across 14+ countries in the GCC, Middle East, and African markets.

Is Globalpharma a public or private company?

Globalpharma is a private company. It is classified as corporate owned and is currently operating.

When was Globalpharma founded?

Globalpharma was founded in 1998. It employs 251 to 500 people.

Where is Globalpharma based?

Globalpharma is headquartered in Dubai, United Arab Emirates, in the Middle East region.

How does Globalpharma make money?

Three revenue lines are on record. Generic Pharmaceutical Product Sales are the primary driver. The others are herbal Medicines Distribution and consumer Health Products (GP+ Brand).

Who are Globalpharma's main competitors?

Direct peers on record are Julphar (Gulf Pharmaceutical Industries), Neopharma, SPIMACO Addwaeih, Tabuk Pharmaceuticals and Hikma Pharmaceuticals. EIPICO (Egyptian International Pharmaceutical Industries) is listed as a regional player. Emerging players are Aurobindo Pharma, Cipla and Sun Pharmaceutical Industries. Sanofi (MENA operations) is listed as a broad incumbent.

Does Globalpharma have an API?

No public API is recorded for Globalpharma.

What industry is Globalpharma in?

Globalpharma's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIABAH, Generic Finished Dosage Form (FDF) Manufacturing, with a secondary code of HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
LogisticsGulfGlobalpharma and PrinceFarma sign MoU to advance pharmaceutical distribution in AngolaGlobalpharma and PrinceFarma signed an MoU to advance pharmaceutical distribution in Angola. The collaboration will evaluate regulatory and distribution pathways for Globalpharma's portfolio, including priority therapeutic areas. PrinceFarma will support distribution, complementing Globalpharma's plans to establish manufacturing operations in Angola.ZawyaGlobalpharma cuts 11,400 tonnes of CO₂ with solar expansionGlobalpharma installed a 612 kWp rooftop solar system at its Dubai manufacturing facility, cutting its carbon footprint by about 11,400 tonnes of CO₂. The system is expected to generate 25.3 GWh of clean energy and is fully operational under Dubai's Shams Dubai programme.ZawyaMubadala Bio unveils new brand identities for IDS and GMSCMubadala Bio announced new brand identities for Al Ittihad Drug Store (IDS) and Global Medical Supply Chain (GMSC) to reflect their expanded strategic role in life sciences. The rebrand follows full acquisition earlier this year, with IDS signing agreements with L-Nutra, Valeo Health, Bayer, and Globalpharma, and GMSC opening a 2,500 sqm warehouse in KEZAD.ZawyaGlobalpharma signs 7 strategic MoUs advancing R&D, manufacturing and sustainabilityGlobalpharma signed seven strategic MoUs with partners to advance R&D, manufacturing, and sustainability. The collaborations include ZIM Laboratories, Masibus, Rockwell Automation, and 386 Sky Solar, with a 612 kWp rooftop PV plant expected to generate 25.3 GWh and avoid 11,400 tonnes of CO₂ emissions.The Times of IndiaZIM Labs inks pact with Globalpharma Co to commercialise oral thin film products - The Economic TimesZIM Laboratories Ltd has signed a licensing and supply agreement with UAE-based Globalpharma Co to commercialize oral thin film (OTF) products in the Gulf Cooperation Council (GCC) region. The agreement grants Globalpharma a dossier license, product supply, and technology know-how license for ZIM's proprietary 'ThinOral' OTF technology platform, enabling the registration and commercialization of 10 OTF-based pharmaceutical and nutraceutical products. ZIM will initially supply bulk products with regulatory support for UAE market registration, and post-approval will deliver ready-to-use powder mixes for localized manufacturing.